Oncology PracticeLenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumorsJanuary 31, 2020Renal Cell CarcinomaImmuno-oncologyGenitourinary CancerMelanomaLung CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeDual immunotherapy goes the distance in MSI-H colorectal cancerJanuary 29, 2020GastroenterologyImmuno-oncologyGI OncologyGastrointestinal Cancer
Oncology PracticeT-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma studyJanuary 24, 2020Sarcoma & GISTImmuno-oncology
Hematology NewsExperts break down latest CAR T-cell advances in lymphomaJanuary 22, 2020B Cell LymphomaCellular TherapyImmuno-oncologyImmunotherapyLymphoma & Plasma Cell DisordersMantle Cell Lymphoma
Hematology NewsCAR T cells produce complete responses in T-cell malignanciesJanuary 7, 2020ALLT Cell LymphomasCellular TherapyLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersImmunotherapyImmuno-oncology
Hematology NewsCAR T-cell therapy advances in CLLDecember 26, 2019CLLCellular TherapyB Cell LymphomaLeukemia, Myelodysplasia, TransplantationImmuno-oncologyImmunotherapy
Hematology NewsInhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patientsDecember 23, 2019Multiple MyelomaImmunotherapyLymphoma & Plasma Cell DisordersCellular TherapyImmuno-oncology
Hematology NewsSurvival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019B Cell LymphomaLymphoma & Plasma Cell DisordersDLBCLFollicular LymphomaIndolent LymphomaImmuno-oncologyImmunotherapy
Hematology News‘Real-world’ data show CAR T therapies are cost effectiveDecember 13, 2019Business of MedicineCellular TherapyImmuno-oncologyImmunotherapyPractice Management
Hematology NewsAn off-the-shelf drug to rival CAR T cells: ‘very exciting’December 13, 2019B Cell LymphomaCellular TherapyLymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Oncology PracticePembrolizumab plus chemo boosts pCR rate in TNBCDecember 13, 2019Breast CancerImmuno-oncology
Hematology NewsOff-the-shelf cellular therapy shows promise in the labDecember 8, 2019B Cell LymphomaCLLCellular TherapyImmuno-oncologyImmunotherapy
Hematology NewsBispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Multiple MyelomaCellular TherapyImmuno-oncologyImmunotherapyLymphoma & Plasma Cell Disorders
Hematology NewsHigh complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaCellular TherapyImmuno-oncologyImmunotherapyLymphoma & Plasma Cell DisordersRare Diseases
Oncology PracticePatient-reported outcomes support first-line pembrolizumab for NSCLCDecember 6, 2019Lung CancerImmuno-oncology
